|By mouth (0.5% solution)|
|Metabolism||Extensive liver (sulfoxidation); first pass effect|
|Elimination half-life||6.3 hours (mitratapide), up to 44.7 hours (metabolites)|
|Chemical and physical data|
|Molar mass||717.28 g/mol|
|3D model (JSmol)|
Mitratapide is a veterinary drug for the treatment of overweight and obese dogs sold under the brand name Yarvitan. Its mechanism of action involves inhibition of microsomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietary lipids. Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.
Mitratapide (under the brand name Yarvitan) was authorized for use in the EU by the European Medicines Agency for helping weight loss in dogs, but it has since been withdrawn from the market in the EU.
- "Yarvitan 5 mg/ml Oral Solution for Dogs. Summary of Product Characteristics" (PDF). www.ema.europa.eu. Retrieved 27 August 2016.
- "Yarvitan (mitratapide). Scientific Discussion" (PDF). www.ema.europa.eu. Retrieved 27 August 2016.
- Mitratapide Archived 2012-04-05 at the Wayback Machine., vetstream.com
- Dobenecker, B; De Bock, M; Engelen, M; Goossens, L; Scholz, A; Kienzle, E (2009). "Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles". Veterinary Research Communications. 33 (8): 839–47. doi:10.1007/s11259-009-9232-5. PMC 2776940. PMID 19544001.
- German, AJ (20 October 2016). "Weight management in obese pets: the tailoring concept and how it can improve results". Acta veterinaria Scandinavica. 58 (Suppl 1): 57. doi:10.1186/s13028-016-0238-z. PMC 5073926. PMID 27766974.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|
|This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it.|